Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2025 08:00 ET | Quelle: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases

Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic ValidationClinical Data Build Upon Robust Preclinical Activity Seen...
11. Juni 2025 08:00 ET | Quelle: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601

Study met primary endpoint of safety and tolerability at all doses and secondary pharmacodynamic and pharmacokinetic endpoints after single subcutaneous administrationPharmacodynamics provides...
07. Mai 2025 09:55 ET | Quelle: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences

Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management teamIncludes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data...